<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015586</url>
  </required_header>
  <id_info>
    <org_study_id>HR#19550</org_study_id>
    <secondary_id>K23AA017666</secondary_id>
    <nct_id>NCT01015586</nct_id>
  </id_info>
  <brief_title>Treatment of Alcohol Dependence and Comorbid Bipolar Disorder</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine if individuals with co-occurring bipolar disorder and alcohol
      dependence report reduced alcohol consumption, improvement in mood symptoms, and cognitive
      performance if treated with lamotrigine plus their usual mood stabilizing medications
      relative to subjects treated with placebo plus usual mood stabilizing medications over a 16
      week period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Days Abstinent From Alcohol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of days in trial without consumption of alcoholic beverages per participant self-report; minimum = 0, maximum = 100; higher numbers indicate better outcome. Percent days abstinent was calculated as: (number of days abstinent per self-report / total number of days in trial)*100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Heavy Drinking Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of days in trial that were heavy drinking days (5 or more drinks/day for men, 4 or more drinks/day for women); minimum = 0, maximum = 100; lower numbers indicate better outcome. Percent heavy drinking days was calculated as: (number of days of heavy drinking per self-report / total number of days in trial)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Alcohol Use: Carbohydrate-deficient Transferrin (CDT)</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Serum levels of biomarkers of alcohol use: carbohydrate-deficient transferrin (CDT) at study endpoint in study completers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Alcohol Use: Gamma-glutamyltransferase (GGT)</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Serum levels of biomarkers of alcohol use: Gamma-glutamyltransferase (GGT) at study endpoint in study completers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS) Score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Scores on the Montgomery-Asberg Depression Rating Scale (MADRS) at baseline (all randomized subjects) and at study endpoint (study completers). Scores represent total summed score of ten (10) subscale items; minimum = 0, maximum = 60, higher scores indicate worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS) Scores</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Mania/hypomania symptoms at study endpoint as assessed by the Young Mania Rating Scale (YMRS) at baseline (all randomized subjects) and at study endpoint (study completers). Scores represent total summed score of eleven (11) subscale items; minimum = 0, maximum = 60, higher scores indicate worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance (California Verbal Learning Test)</measure>
    <time_frame>Study endpoint 12 weeks after randomization</time_frame>
    <description>Adjusted scale scores (T scores) on the California Verbal Learning Test (CVLT) of verbal working memory at study endpoint. CVLT Trials 1-5 Free Recall Total measures the sum of all word list items correctly recalled on learning trials 1 through 5. This raw score is converted to a T-score (mean = 50; SD=10) with higher scores indicating better performance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <condition>Mania</condition>
  <condition>Psychosis</condition>
  <arm_group>
    <arm_group_label>Lamotrigine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
    <arm_group_label>Lamotrigine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  Meet DSM-IV-TR criteria for current alcohol dependence with active alcohol use in the
             past 30 days

          -  Meet DSM-IV-TR criteria for bipolar I or bipolar II disorder

          -  Have average alcohol consumption of at least 35 drinks/week for men, 28 drinks/week
             for women in the last 4 weeks of active drinking prior to enrollment.

          -  Able to provide informed consent and function at an intellectual level sufficient to
             allow accurate completion of the assessment instruments.

          -  Must consent to random assignment and be willing to commit to medication treatment and
             follow-up assessments.

          -  Currently under the care of a psychiatrist.

          -  Must consent to sign a release of information allowing investigators to communicate
             with his/her psychiatrist to verify treatment history and facilitate care should
             treatment-emergent psychiatric symptoms develop during the trial.

          -  Currently taking a therapeutic dosage of one or more mood stabilizing medications as
             defined by one or more of the following:

               -  Lithium level of 0.6 - 1.2 mEq/L

               -  Prescribed daily use of first generation antipsychotic agents including
                  chlorpromazine, fluphenazine, or haloperidol or their injectible depot
                  (decanoate) equivalents at a dose adequate to maintain clinical stability as
                  documented by the subject's outpatient psychiatric provider c) Prescribed daily
                  use of second generation antipsychotic agents including olanzapine, risperidone,
                  paliperidone, quetiapine, aripiprazole, or ziprasidone or their injectible depot
                  equivalent at a dose adequate to maintain clinical stability as documented by the
                  subject's outpatient psychiatric provider

          -  Stable psychiatric symptoms as defined by no changes to psychotropic drug regimen for
             30 days

          -  Must agree to identify collateral individuals for contact to facilitate follow-up
             appointments

        Exclusion Criteria:

          -  A primary psychiatric diagnosis other than bipolar disorder

          -  Any uncontrolled neurologic condition (e.g. epilepsy) that could confound the results
             of the study

          -  Any history of Stevens-Johnson syndrome or other severe rash requiring hospitalization

          -  Any history of head injury with loss of consciousness greater than 30 minutes

          -  Any history of learning disability, alcoholic dementia, or electroconvulsive therapy
             in the past 3 months

          -  Any uncontrolled medical condition that may adversely affect the conduct of the trial
             or jeopardize the safety of the subject

          -  Plasma levels of liver transaminases (AST, ALT) greater than 3 times the normal range

          -  Concomitant use of valproic acid

          -  Concomitant use of carbamazepine, oxcarbazepine, phenytoin, primidone, or
             phenobarbital

          -  Concomitant use of disulfiram, naltrexone, acamprosate, or topiramate

          -  Concomitant use of benzodiazepines or any other medications not allowed per the
             protocol

          -  Women of childbearing potential who are pregnant, lactating, or refuse adequate forms
             of contraception

          -  Current suicidal or homicidal risk

          -  Baseline scores of more than 35 on the Montgomery-Asberg Depression Rating Scale or
             more than 16 on the Young Mania Rating Scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan K Tolliver, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen T Brady, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <results_first_submitted>November 7, 2018</results_first_submitted>
  <results_first_submitted_qc>January 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2019</results_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Manic depression</keyword>
  <keyword>Addiction</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Cognitive impairment</keyword>
  <keyword>Executive function</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Depression</keyword>
  <keyword>Mania</keyword>
  <keyword>Affective disorder</keyword>
  <keyword>Psychosis</keyword>
  <keyword>Carbohydrate deficient transferrin</keyword>
  <keyword>Gammaglutamyltransferase</keyword>
  <keyword>California Verbal Learning Test</keyword>
  <keyword>Montgomery Asberg Depression Rating Scale</keyword>
  <keyword>Young Mania Rating Scale</keyword>
  <keyword>Timeline Follow Back</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lamotrigine</title>
          <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lamotrigine</title>
          <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.48" spread="11.46"/>
                    <measurement group_id="B2" value="44.14" spread="10.13"/>
                    <measurement group_id="B3" value="44.30" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Days Abstinent From Alcohol</title>
        <description>Percentage of days in trial without consumption of alcoholic beverages per participant self-report; minimum = 0, maximum = 100; higher numbers indicate better outcome. Percent days abstinent was calculated as: (number of days abstinent per self-report / total number of days in trial)*100.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analysis is of modified intention to treat (ITT) sample comprised of all randomized subjects who returned for at least one study visit after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Lamotrigine</title>
            <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Abstinent From Alcohol</title>
          <description>Percentage of days in trial without consumption of alcoholic beverages per participant self-report; minimum = 0, maximum = 100; higher numbers indicate better outcome. Percent days abstinent was calculated as: (number of days abstinent per self-report / total number of days in trial)*100.</description>
          <population>Analysis is of modified intention to treat (ITT) sample comprised of all randomized subjects who returned for at least one study visit after randomization.</population>
          <units>Percentage of days abstinent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="30.0"/>
                    <measurement group_id="O2" value="80.1" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Heavy Drinking Days</title>
        <description>Percentage of days in trial that were heavy drinking days (5 or more drinks/day for men, 4 or more drinks/day for women); minimum = 0, maximum = 100; lower numbers indicate better outcome. Percent heavy drinking days was calculated as: (number of days of heavy drinking per self-report / total number of days in trial)*100.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analysis is of modified intention to treat (mITT) sample comprised of all randomized subjects who returned for at least one study visit after randomization (total mITT sample n=37).</population>
        <group_list>
          <group group_id="O1">
            <title>Lamotrigine</title>
            <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Heavy Drinking Days</title>
          <description>Percentage of days in trial that were heavy drinking days (5 or more drinks/day for men, 4 or more drinks/day for women); minimum = 0, maximum = 100; lower numbers indicate better outcome. Percent heavy drinking days was calculated as: (number of days of heavy drinking per self-report / total number of days in trial)*100.</description>
          <population>Analysis is of modified intention to treat (mITT) sample comprised of all randomized subjects who returned for at least one study visit after randomization (total mITT sample n=37).</population>
          <units>Percentage of heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="12.8"/>
                    <measurement group_id="O2" value="11.6" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Alcohol Use: Carbohydrate-deficient Transferrin (CDT)</title>
        <description>Serum levels of biomarkers of alcohol use: carbohydrate-deficient transferrin (CDT) at study endpoint in study completers</description>
        <time_frame>12 weeks after randomization</time_frame>
        <population>The sample analyzed is limited to study completers (total n=25) due to this measure being obtained at study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Lamotrigine</title>
            <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Alcohol Use: Carbohydrate-deficient Transferrin (CDT)</title>
          <description>Serum levels of biomarkers of alcohol use: carbohydrate-deficient transferrin (CDT) at study endpoint in study completers</description>
          <population>The sample analyzed is limited to study completers (total n=25) due to this measure being obtained at study endpoint.</population>
          <units>&quot;percent CDT&quot;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread=".48"/>
                    <measurement group_id="O2" value="1.26" spread=".18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Alcohol Use: Gamma-glutamyltransferase (GGT)</title>
        <description>Serum levels of biomarkers of alcohol use: Gamma-glutamyltransferase (GGT) at study endpoint in study completers</description>
        <time_frame>12 weeks after randomization</time_frame>
        <population>Sample in this analysis is limited to study completers only (total n=25) because this measure was obtained at study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Lamotrigine</title>
            <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Alcohol Use: Gamma-glutamyltransferase (GGT)</title>
          <description>Serum levels of biomarkers of alcohol use: Gamma-glutamyltransferase (GGT) at study endpoint in study completers</description>
          <population>Sample in this analysis is limited to study completers only (total n=25) because this measure was obtained at study endpoint.</population>
          <units>Units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="139.4"/>
                    <measurement group_id="O2" value="22.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery-Asberg Depression Rating Scale (MADRS) Score</title>
        <description>Scores on the Montgomery-Asberg Depression Rating Scale (MADRS) at baseline (all randomized subjects) and at study endpoint (study completers). Scores represent total summed score of ten (10) subscale items; minimum = 0, maximum = 60, higher scores indicate worse outcomes.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All randomized subjects (total n=43) included in analysis at baseline. Study completers only (total n=25) included in analysis at study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Lamotrigine</title>
            <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS) Score</title>
          <description>Scores on the Montgomery-Asberg Depression Rating Scale (MADRS) at baseline (all randomized subjects) and at study endpoint (study completers). Scores represent total summed score of ten (10) subscale items; minimum = 0, maximum = 60, higher scores indicate worse outcomes.</description>
          <population>All randomized subjects (total n=43) included in analysis at baseline. Study completers only (total n=25) included in analysis at study endpoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline MADRS score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.86" spread="5.34"/>
                    <measurement group_id="O2" value="12.05" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MADRS score at study endpoint</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="5.36"/>
                    <measurement group_id="O2" value="9.18" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Young Mania Rating Scale (YMRS) Scores</title>
        <description>Mania/hypomania symptoms at study endpoint as assessed by the Young Mania Rating Scale (YMRS) at baseline (all randomized subjects) and at study endpoint (study completers). Scores represent total summed score of eleven (11) subscale items; minimum = 0, maximum = 60, higher scores indicate worse outcomes.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Baseline YMRS scores include all randomized subjects (total n=43). Study endpoint YMRS scores include study completers only (total n=25).</population>
        <group_list>
          <group group_id="O1">
            <title>Lamotrigine</title>
            <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Young Mania Rating Scale (YMRS) Scores</title>
          <description>Mania/hypomania symptoms at study endpoint as assessed by the Young Mania Rating Scale (YMRS) at baseline (all randomized subjects) and at study endpoint (study completers). Scores represent total summed score of eleven (11) subscale items; minimum = 0, maximum = 60, higher scores indicate worse outcomes.</description>
          <population>Baseline YMRS scores include all randomized subjects (total n=43). Study endpoint YMRS scores include study completers only (total n=25).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline YMRS scores</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" spread="4.50"/>
                    <measurement group_id="O2" value="9.25" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint YMRS scores</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="2.65"/>
                    <measurement group_id="O2" value="7.40" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance (California Verbal Learning Test)</title>
        <description>Adjusted scale scores (T scores) on the California Verbal Learning Test (CVLT) of verbal working memory at study endpoint. CVLT Trials 1-5 Free Recall Total measures the sum of all word list items correctly recalled on learning trials 1 through 5. This raw score is converted to a T-score (mean = 50; SD=10) with higher scores indicating better performance.</description>
        <time_frame>Study endpoint 12 weeks after randomization</time_frame>
        <population>Sample analyzed includes study completers only (total n=25) as this measure was obtained at study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Lamotrigine</title>
            <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance (California Verbal Learning Test)</title>
          <description>Adjusted scale scores (T scores) on the California Verbal Learning Test (CVLT) of verbal working memory at study endpoint. CVLT Trials 1-5 Free Recall Total measures the sum of all word list items correctly recalled on learning trials 1 through 5. This raw score is converted to a T-score (mean = 50; SD=10) with higher scores indicating better performance.</description>
          <population>Sample analyzed includes study completers only (total n=25) as this measure was obtained at study endpoint.</population>
          <units>T scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="14.6"/>
                    <measurement group_id="O2" value="52.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks (two-week baseline assessment phase, 12 week active medication phase, 4 week safety phase after medication discontinuation)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lamotrigine</title>
          <description>Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
Lamotrigine: Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
Placebo: Placebo once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Active suicidal ideation with plan to overdose on medications</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization (medical) after assault</sub_title>
                <description>Neurosurgical evacuation of epidural hematoma, intensive care required after serious assault</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema / skin discoloration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Papular skin eruption</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively small sample size, suboptimal retention rate (58% of all randomized subjects)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bryan K. Tolliver, MD PhD</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-4869</phone>
      <email>tollive@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

